Ro Partners with Eli Lilly to Offer Lower-Priced Zepbound Vials with Cash-Pay Option

Dec 11, 2024, 01:42 PM

Telehealth company Ro has partnered with pharmaceutical giant Eli Lilly to expand access to Zepbound, a weight-loss drug containing tirzepatide. The partnership will enable Ro to offer lower-priced, single-dose vials of Zepbound through LillyDirect, Eli Lilly's self-pay pharmacy channel. Ro patients with on-label prescriptions will have access to the drug starting Wednesday, with a cash-pay option available. This collaboration comes amid ongoing shortages of semaglutide-based drugs, such as Ozempic, and questions about the future of compounded GLP-1 treatments. The announcement has impacted the stock performance of Hims & Hers Health, Inc. (HIMS), a company that sells compounded semaglutide, with shares falling 3.8% pre-market.